<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Vote</th>
</tr>
</thead>
</table>
| ESOPH-F 4 and 11           | Internal Request  
Comment to add irinotecan and ramucirumab for adenocarcinoma as a second-line or subsequent therapy option.  
Based on the review of the data in the noted reference, the panel consensus was to include irinotecan and ramucirumab for adenocarcinoma as a second-line or subsequent therapy option for unresectable locally advanced, recurrent, or metastatic disease. This is a category 2A [other recommended] recommendation.  
Reference  
NO 2  
ABSTAIN 7  
ABSENT 6 |
| ESOPH-F 4 and 11           | Internal request  
Comment request to reassess the data for the inclusion of fluorouracil and irinotecan + ramucirumab for adenocarcinoma within the Guidelines as a second-line or subsequent therapy option.  
Based on the review of the data, the panel consensus supported the continued inclusion of fluorouracil and irinotecan + ramucirumab for adenocarcinoma as a second-line or subsequent therapy option for unresectable locally advanced, recurrent, or metastatic disease. This is a category 2A (other recommended) recommendation.  
Previously it was a category 2B (useful in certain circumstances) recommendation. | YES 20  
NO 1  
ABSTAIN 4  
ABSENT 6 |